Baraṣ (Vitiligo) in Historical and Unani Literature: A Comprehensive Review
Abstract
Baraṣ (Vitiligo) is a chronic depigmentary disorder marked by well-demarcated glossy white macules due to selective loss or dysfunction of melanocytes, causing significant psychosocial morbidity despite being nonfatal. The review traces historical descriptions of Baraṣ across Unani, Ayurvedic, GrecoRoman and other classical texts, and synthesizes classical Unani concepts including Fasād al-Dam, Balghami Ghalīẓ, weakness of Quwwat-i Mughayyira/Mushabbiha/Dāfi‘a, and prognostic signs such as bleeding on pricking with contemporary pathophysiological models (autoimmune, neural, oxidative stress, genetic susceptibility and convergence theory). Clinical classification parallels modern nosology (nonsegmental, segmental, mixed), while Unani subtypes (Baraṣ-i Uẓmā, Baraṣ-i Muntashir) emphasize depth and chronicity of humoural involvement. Diagnosis relies on clinical examination complemented by Wood’s lamp, targeted laboratory screening for associated autoimmune disorders (notably thyroid disease), and, when indicated, biopsy. Therapeutic strategies integrate Unani principles Tanqiya-i Badan, Ta’dili Mizāj, Islāhi Haḍm, topical Jālī/Muḥammir/Musakhkhin agents, and regimental therapies with evidencebased modern treatments such as topical corticosteroids, calcineurin inhibitors, NBUVB phototherapy, and surgical grafting for stable lesions. The review highlights areas of concordance (sun exposure/psoralen use historically and in PUVA), identifies limitations in prognostication, and advocates for rigorous clinical trials to evaluate Unani single and compound formulations alongside conventional modalities. Integration of traditional Unani approaches with modern dermatological care may offer a holistic, patientcentred pathway for managing Baraṣ, but requires standardized protocols and safetyefficacy data.
Keywords: Vitiligo, Baraṣ, Unani Medicine, PUVA
Keywords:
Vitiligo, Baraṣ, PUVA, Unani MedicineDOI
https://doi.org/10.22270/jddt.v16i9.7961References
1. Allam M, Riad H. Concise review of recent studies in vitiligo. Qatar Med J. 2013;2013(2):1-19. https://doi.org/10.5339/qmj.2013.10 PMid:25003059 PMCid:PMC4080492
2. Gauthier Y, Cario-André M, Lepreux S, Pain C, Taïeb A. Melanocyte detachment after skin friction in nonlesional skin of patients with generalized vitiligo. Br J Dermatol. 2003;148(1):95-101. https://doi.org/10.1046/j.1365-2133.2003.05024.x PMid:12534601
3. Ezzedine K, Gauthier Y, Léauté-Labrèze C, Marquez S, Bouchtnei S, Jouary T, et al. Segmental vitiligo associated with generalized vitiligo (mixed vitiligo): a retrospective case series of 19 patients. J Am Acad Dermatol. 2011;65(5):965-971. https://doi.org/10.1016/j.jaad.2010.08.031 PMid:21616559
4. Picardo M, Taïeb A, editors. Vitiligo. Berlin: Springer; 2010. doi:10.1007/978-3-540-69361-1. ISBN-13:978-3-540-69360-4 (print); 978-3-540-69361-1 (eBook).
5. Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206-1212. https://doi.org/10.1111/j.1365-4632.2011.05377.x PMid:22458952
6. Behl PN, Bhatia RK. 400 cases of vitiligo: a clinico-therapeutic analysis. Indian J Dermatol. 1972;17(2):51-56. PMID:5039893.
7. Howitz J, Brodthagen H, Schwartz M, Thomsen K. Prevalence of vitiligo: epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol. 1977;113(1):47-52. PMid:831622 https://doi.org/10.1001/archderm.1977.01640010049006
8. Lerner AB, Nordlund JJ. Vitiligo: what is it? Is it important? JAMA. 1978;239(12):1183-1187.. https://doi.org/10.1001/jama.1978.03280390079031 PMid:628076
9. Sehgal VN, Srivastava G. Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol. 2007;73(3):149-15. https://doi.org/10.4103/0378-6323.32708 PMid:17558045
10. Dutta AK. Vitiligo: neural and immunologic linkages. Calcutta: Indira Publication; 1988. p. 13-26.
11. Warrell DA, Cox TM, Firth JD, editors. Oxford textbook of medicine. Oxford: Oxford University Press; 2010. https://doi.org/10.1093/med/9780199204854.001.1
12. Ongenae K, Beelaert L, van Geel N, Naeyaert JM. Psychosocial effects of vitiligo. J Eur Acad Dermatol Venereol. 2006;20(1):1-8. https://doi.org/10.1111/j.1468-3083.2005.01369.x PMid:16405601
13. Rabban Ṭabarī AHA bin S. Firdaws al-Hikmat [Urdu]. Sanabehli HMAS, editor. New Delhi: H.S. Offset Press; 2010. p. 294-297.
14. Rāzī ABM ibn Z. Kitab al-Hawi fi’l Tibb [Arabic]. 1st ed. Vol. 23, part II. Hyderabad: Dairatul Ma’arif, Osmania University; [year unknown]. p. 88-119.
15. Ṭabrī A Ḥasan A bin M. Al-Mu’ālajat al-Buqrāṭiya. Vol. 2. New Delhi: Central Council for Research in Unani Medicine; 1997. p. 199-200.
16. Gāzrūnī S al-D. Al-Sadīdī [Arabic]. Lucknow: Maṭba Munshi Nawal Kishor; [year unknown]. p. 61-62.
17. Majusi AIA. Kamil al-Sana [Urdu translation by Kanturi HGH]. Vol. 2, part 1. New Delhi: Central Council for Research in Unani Medicine; 2010. p. 427-429.
18. Ibn Sīnā al-S al-RA ‘Ali al-H ibn ‘Abd A. Al-Qānūn fi’l Ṭibb. 1st ed. Kantoori GH, editor. Lahore: Shaikh Muhammad Basheer and Sons, Urdu Bazar; [year unknown]. p. 351-353.
19. IH Baghdadi AHA bin A bin A. Kitab al-Mukhtarat fi’l-Tibb [Urdu translation]. Vol. 4. New Delhi: Central Council for Research in Unani Medicine; 2007. p. 127-130.
20. Jurjani AHI. Zakhira Khwarizm Shahi [Urdu translation]. Khan HHH, translator. New Delhi: Idara Kitab-us-Shifa; 2010.
21. Antaki SDA. Tazkira Awliya al-Albab [Arabic]. 4th ed. Vol. 2. Cairo: Azharia Press; 1924.
22. Azam Khan HM. Ikseer-e-Azam [Persian]. Vol. 4. Lucknow: Munshi Nawal Kishore Press; 1885. p. 475-487.
23. Husain AHM, editor. Ṭibb-i Akbar. Deoband: Faisal Publications, Jama Masjid; [year unknown]. p. 731-732.
24. M.H.Q. Ghina Muna [Urdu translation]. CCRUM, editor. New Delhi: Central Council for Research in Unani Medicine; 2008. p. 458-462.
25. Gāzrūnī S al-D. Al-Sadīdī [Arabic]. Lucknow: Maṭba Munshi Nawal Kishor; [year unknown]. p. 61-62.
26. Central Council for Research in Unani Medicine. Standard Unani treatment guidelines for common diseases. New Delhi: Central Council for Research in Unani Medicine; 2014. p. 180-182. ISBN:81-87748-42-7.
27. Ongenae K, van Geel N, Naeyaert J. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003;16(2):90-100. https://doi.org/10.1034/j.1600-0749.2003.00023.x PMid:12622785
28. Passeron T, Ortonne JP. Physiopathology and genetics of vitiligo. J Autoimmun. 2005;25 Suppl:63-68. https://doi.org/10.1016/j.jaut.2005.10.001 PMid:16298511
29. Hann SK, Chun WH. Autocytotoxic hypothesis for the destruction of melanocytes as the cause of vitiligo. In: Hann SK, Nordlund JJ, editors. Vitiligo: a monograph on the basic and clinical science. Oxford: Blackwell Science; 2000. p. 137-141. https://doi.org/10.1002/9780470760116.ch17
30. Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CCE, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25(3):E1-E13. https://doi.org/10.1111/j.1755-148X.2012.00997.x PMid:22417114 PMCid:PMC3511780
31. Taïeb A, Ezzedine K. Vitiligo: the white armour? Pigment Cell Melanoma Res. 2013;26(3):286-299. https://doi.org/10.1111/pcmr.12076 PMid:23490075
32. Passeron T, Ortonne JP. Generalized vitiligo. In: Picardo M, Taïeb A, editors. Vitiligo. Berlin: Springer; 2010. p. 35-39.. https://doi.org/10.1007/978-3-540-69361-1_4
33. Fargnoli MC, Bolognia JL. Pentachrome vitiligo. J Am Acad Dermatol. 1995;33(5 Pt 2):853-856.. https://doi.org/10.1016/0190-9622(95)90422-0 PMid:7593796
34. Hann SK, Lee HJ. Segmental vitiligo: clinical findings in 208 patients. J Am Acad Dermatol. 1996;35(5 Pt 1):671-674.. https://doi.org/10.1016/S0190-9622(96)90718-5 PMid:8912558
35. Halder RM, Grimes PE, Cowan CA, Enterline JA, Chakrabarti SG, Kenney JA Jr. Childhood vitiligo. J Am Acad Dermatol. 1987;16(5 Pt 1):948-954. https://doi.org/10.1016/S0190-9622(87)70119-4 PMid:3584578
36. Dave S, Thappa DM, Dsouza M. Clinical predictors of outcome in vitiligo. Indian J Dermatol Venereol Leprol. 2002;68(6):323-325. PMID:17656989.
37. Harning R, Cui J, Bystryn JC. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol. 1991;97(6):1078-1080. https://doi.org/10.1111/1523-1747.ep12492607 PMid:1748818
38. Dhar S, Datta P, Malakar R. Pigmentary disorders. In: Valia RG, Valia AR, editors. IADVL Textbook of Dermatology. 3rd ed. Mumbai: Bhalani Publishing House; 2008. p. 749-760.
39. Koga M. Vitiligo: a new classification and therapy. Br J Dermatol. 1977;97(3):255-261. https://doi.org/10.1111/j.1365-2133.1977.tb15180.x PMid:921895
40. Taïeb A, Picardo M. Epidemiology, definitions and classification. In: Picardo M, Taïeb A, editors. Vitiligo. Berlin: Springer; 2010. p. 13-24. doi:10.1007/978-3-540-69361-1_2 https://doi.org/10.1007/978-3-540-69361-1_2
41. Faria AR, Tarlé RG, Dellatorre G, Mira MT, de Castro CCS. Vitiligo-part 2-classification, histopathology and treatment. An Bras Dermatol. 2014;89(5):784-790. https://doi.org/10.1590/abd1806-4841.20142717 PMid:25184918 PMCid:PMC4155957
42. Lotti T, Berti S, Moretti S. Vitiligo therapy. Expert Opin Pharmacother. 2009;10(17):2779-2785.. https://doi.org/10.1517/14656560903357509 PMid:19929701
43. Husain N, Uddin Q, Kazmi MH. Clinical studies on the treatment of Baras (vitiligo) in Unani system of medicine: a systematic review. Eur J Biomed Pharm Sci. 2018;5:1088-1094. doi:10.5281/zenodo.6762059.
44. Samarqandi AN. Mualajat, Sharah Asbab (Tarjuma Kabir Mukammal). Vols. 3-4. Ibn Aewaz Kirmani AN, Kabiruddin AH, editors. Delhi: Idara Kitab-us-Shifa; 2009. p. 340-342.
45. Ali MI, Khan MMA, Shakera AR. Seminar on Bars (Leucoderma), 10th-11th March 1979, Hyderabad. Hyderabad: Central Council for Research in Unani Medicine; 1979. p. 6.
46. Khan MA. Muhit-i-Azam. Vol. 4. Lucknow: Munshi Nawal Kishore Press; 1920.
47. Hakeem MA. Bustanul Mufradat. New Delhi: Idara Kitab-us-Shifa; 2002. p. 81-82, 226, 598-599.
48. Najmul Ghanī. Khazā’in al-Adwiya. New Delhi: Idara Kitab-us-Shifa; [year unknown]. p. 162, 987, 1631, 171-173.
49. Qarābādīn-ī Āzam wa Akmal [Urdu translation]. Delhi: Central Council for Research in Unani Medicine, Ministry of Health and Family Welfare; [year unknown]. p. 7.
50. Anonymous. Qarābādīn Majīdī. Delhi: Ajanta Offset and Packaging Limited; 1986. p. 155-194.
51. Qarābādīn Sarkārī. New Delhi: Central Council for Research in Unani Medicine; 2002. p. 83.
52. Kabīruddīn. Bayāḍ-i-Kabīr. New Delhi: Idara Kitab-us-Shifa; 2010. p. 240, 282.
53. Hakeem H Abdul. Qarabadi-e-Jadid. New Delhi: Central Council for Research in Unani Medicine, Ministry of Health and Family Welfare; 2005. p. 102-103, 103-146.
54. Husain N, Uddin Q, Kazmi MH, Khalid M. A non-inferiority randomized controlled clinical trial comparing Unani formulations and PUVAsol in non-segmental vitiligo. J Complement Integr Med. 2023;20(1):250-257. https://doi.org/10.1515/jcim-2021-0057 PMid:34162019
55. Thakur V, Bishnoi A, Vinay K, Kumaran SM, Parsad D. Vitiligo: translational research and effective therapeutic strategies. Pigment Cell Melanoma Res. 2021;34(4):814-826. https://doi.org/10.1111/pcmr.12974 PMid:33756039
56. Seneschal J, Boniface K, D’Arino A, Picardo M. An update on vitiligo pathogenesis. Pigment Cell Melanoma Res. 2021;34(2):236-243. https://doi.org/10.1111/pcmr.12949 PMid:33278065
57. Bergqvist C, Ezzedine K. Vitiligo: a focus on pathogenesis and its therapeutic implications. J Dermatol. 2021;48(3):252-270. https://doi.org/10.1111/1346-8138.15743 PMid:33404102
58. Böhm M, Schunter JA, Fritz K, Salavastru C, Dargatz S, Augustin M, et al. S1 guideline: diagnosis and therapy of vitiligo. J Dtsch Dermatol Ges. 2022;20(3):365-378. https://doi.org/10.1111/ddg.14713
59. Chang WL, Ko CH. The role of oxidative stress in vitiligo: an update on its pathogenesis and therapeutic implications. Cells. 2023;12(6):936. https://doi.org/10.3390/cells12060936 PMid:36980277 PMCid:PMC10047323
60. Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445-1455. https://doi.org/10.1056/NEJMoa2118828 PMid:36260792
61. Farajzadeh S, Khalili M, Mirmohammadkhani M, Paknazar F, Rastegarnasab F, Abtahi-Naeini B. Global clinicoepidemiological pattern of childhood vitiligo: a systematic review and meta-analysis. BMJ Paediatr Open. 2023;7(1):e001839. https://doi.org/10.1136/bmjpo-2022-001839 PMid:37616066 PMCid:PMC10083860
62. Castillo E, González-Rosende ME, Martínez-Solís I. The use of herbal medicine in the treatment of vitiligo: an updated review. Planta Med. 2023;89(5):468-483. https://doi.org/10.1055/a-1855-1839 PMid:36379447
63. van Geel N, Speeckaert R, Taïeb A, Ezzedine K, Lim HW, Pandya AG, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force-Part 1: towards a new management algorithm. J Eur Acad Dermatol Venereol. 2023;37(11):2173-2184. https://doi.org/10.1111/jdv.19451 PMid:37746876
64. Seneschal J, Speeckaert R, Taïeb A, Wolkerstorfer A, Passeron T, Pandya AG, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force-Part 2: specific treatment recommendations. J Eur Acad Dermatol Venereol. 2023;37(11):2185-2195. https://doi.org/10.1111/jdv.19450 PMid:37715487
65. Akl J, Lee S, Ju HJ, Parisi R, Kim JY, Jeon JJ, et al. Estimating the burden of vitiligo: a systematic review and modelling study. Lancet Public Health. 2024;9(6):e386-e396. PMID:38552651. https://doi.org/10.1016/S2468-2667(24)00026-4 PMid:38552651
66. Shah NA, Mir RA, Saltanat S. Understanding and treating baras (vitiligo) in Unani medicine: historical perspectives, pathophysiology, and therapeutic approaches. J Complement Integr Med. 2025;22(3):390-401.. PMID:39331622. https://doi.org/10.1515/jcim-2024-0240 PMid:39331622
67. Prajapati VH, Lui H, Miller-Monthrope Y, Ringuet J, Turchin I, Hong HCH, et al. Canadian consensus guidelines for the management of vitiligo. Dermatol Ther (Heidelb). 2025;15(6):1351-1369. https://doi.org/10.1007/s13555-025-01402-5 PMid:40253664 PMCid:PMC12092322
68. Bhingradia YM, Gupta S, Ghia D, Shah S, Patel NK, Salim T, et al. Consensus statement on the surgical management of vitiligo. J Cutan Aesthet Surg. 2025;18(1):27-33. https://doi.org/10.25259/JCAS_117_2024 PMid:40027541 PMCid:PMC11866675
69. Ansari S, Afzal SMA, Jamal MA, Itrat M. Successful treatment of poliosis associated with vitiligo using Unani medications: a case report. Explore (NY). 2025;21(5):103230.PMID:40780013. https://doi.org/10.1016/j.explore.2025.103230 PMid:40780013
Published
Abstract Display: 11 
PDF Downloads: 13 PDF Downloads: 7 How to Cite
Issue
Section
Copyright (c) 2026 Mohd Tarique, Naila Naaz, Mohammad Zubair, Shaikh Imtiyaz, Mohd Furqan Patel
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.